STRUCTURE BASED
AND LIGAND
BASED DRUG
DESIGNING
VYSAKH MOHAN M
DRUG DESIGNING
INTRODUCTION
 CADD
STRUCTURE BASED DRUG DESIGNING
LIGAND BASED DRUG DESIGNING
Structure based and ligand based drug designing
STRUCTURE BASED AND
LIGAND BASED DRUG
DESIGNING
STRUCTURE
BASED
 Don’t know ligands
 Know receptor
structures
LIGAND BASED
 Don’t know receptors
 Know ligands
Structure based and ligand based drug designing
STRUCTURE-BASED
DRUG DESIGN
STRUCTURE BASED DRUG DESIGNING
 Three dimensional structure of the biological
target
 Obtained through x-ray crystallography or NMT
spectroscopy
 If experimental structure is not available, create a
homology model of the target, based on the
experimental structure of a related protein
 Various automated computational procedures
may be used
STRUCTURE BASED DRUG DESIGNING
 Protein structure determination
 Docking
 Binding free energy
 Flexibility of protein-ligand complex
 De novo evolution
PROTEIN STUCTURE DETERMINATION
 HOMOLOGY MODELING
 Fast method to obtain protein structures
 To ensure the rationality of modelled structures,
checks on stereochemistry, energy profile,
residue environments, and structure similarity
are needed
PROTEIN STUCTURE DETERMINATION
 FOLDING RECOGNITION
 Threading
 Calculates the probabilities of 3D structures
could form by given protein sequences
 Both environment of residues interactions and
protein surface area are considered in the
threading protocol
 Structure with highest probability is
recommended to construct the protein model
PROTEIN STUCTURE DETERMINATION
 Ab initio PROTEIN MODELING
 Based on physical principles, residue interaction
center and lattice representation of a protein to
build the target
 Used when other protocols fail to predict and
unknown protein structure
 Identity and accuracy given by this modelling is
lower than others
PROTEIN STUCTURE DETERMINATION
 HOT SPOT PREDICTION
 One big issue in SBDD is to determine ligand
active site
 Determined using X-ray crystallography
 But not possible for proteins that cannot be
crystallised
 Several binding site determination methods
have been invented
DOCKING
 A method which predicts the preferred
orientation of one molecule to a second when
bound to each other to form a stable complex
save
YES
NO
OK
BETTER
DOCKING TOOLS
 AUTODOCK
 Software AutoDock, developed by Olsen’s
Laboratory
 A program for docking small flexible ligands into a
rigid 3D structure
Structure based and ligand based drug designing
DOCKING TOOLS
 CDOCKER
 This protocol is a docking algorithm and retain all
the advantages of full ligand flexibility
 Uses a sphere to define an active site, so the
knowledge of the binding site is not required
 CHARMM based docking algorithm
DOCKING TOOLS
 FLEXIBLE DOCKING
 Retains receptor flexibility during docking of flexible
ligands
 ChiFlex algorithm
 LibDock program
 Indicates the binding site where ligand polar and
non-polar groups may be bound to the favourable
positions of protein
DOCKING TOOLS
 LIGAND FIT
 A grid-based method for calculating receptor-
ligand interaction energies, which is crucial in initial
ligand shape match to the receptor binding site
 Consists of
 Definition of active site
 Analysis of ligand conformations
 Docking of ligands to a selected site
 Scoring of predicted poses
Structure based and ligand based drug designing
DOCKING TOOLS
 TRANSMEMBRANE PROTEIN MODELING
 There are many medicines that target
transmembrane protein (HER2 and GABA receptor)
 Due to difficulties of crystallisation accurately
analysing transmembrane protein is difficult
 Since there is influence of phospholipid bilayer a
membrane force field option can be included
A modeled GABA receptor with membrane force field.
BINDING FREE ENERGY
 All the docking protocols discussed above do not
include functions for calculating binding free
energy
energy of binding = energy of complex –
energy of ligand –
energy of receptor
FLEXIBILITY OF PROTEIN-
LIGAND COMPLEX
 Flexibility of complex must be studied
 The difference in result of flexible docking and
LigandFit is due to difference in flexibility of
molecules, such that:
Flexibility = score of LigandFit –
score of flexible docking
 The result of molecular simulation is related to
flexibility, and a positive relationship can be
obtained in flexibility vs. molecular dynamics.
De novo EVOLUTION
 After docking program, we can modify ligands by
two methods
 Based on active site features to identify functional
groups that can establish strong interactions with
the receptor. Then, functional groups can be linked
 Using the original ligand scaffolds to develop
derivatives that can complement the receptor
LIGAND-BASED
DRUG DESIGN
LIGAND-BASED DRUG DESIGN
 Relies on knowledge of other molecules that bind
to the biological target of interest
 These other molecules may be used to derive a
pharmacophore model
 Alternatively, a QSAR relationship, in which a
correlation between calculated properties of
molecules and their experimentally determined
biological activity, may be derived
 QSAR may be used to predict the activity of new
analogues
LIGAND-BASED DRUG DESIGN
 Quantitative structure-activity relationship (QSAR)
 CoMFA
 CoMSIA
QUANTITATIVE STRUCTURE-
ACTIVITY RELATIONSHIP
 Employs statistics and analytical tools to
investigate the relationship between the
structures of ligands and their corresponding
effects.
 Mathematical models are built based on
structural parameters to describe
 Earlier 2D-QSAR, but 3D-QSAR have been
adopted
 3D-QSAR methodologies: CoMFA, CoMSIA
CoMFA
 Comparative molecular field analysis
 Biological activity of a molecule is dependent of
the surrounding molecular fields (Steric and
electrostatic fields)
 Has several problems
CoMSIA
 Comparative molecular similarity index analysis
 Includes more additional field properties
 Steric
 Electrostatic
 Hydrophobic
 Hydrogen bond donor
 Hydrogen bond acceptor
 Can offer a more accurate structural-activity
relationship than CoMFA
CONCLUSION
 Molecular simulation has a vital role in drug
design and CADD
 Fast, efficient and inexpensive tool to
 Discover new possible ligands against a
macromolecular target
 Test library design ideas
 Identify most promising scaffolds and R groups prior
to synthesis
THANK YOU

More Related Content

PPTX
Structure based drug design
PPTX
Computer aided drug design(CADD)
PPTX
Drug Designing
PPT
Computer aided drug designing
PPTX
Photo fries rearrangement & Barton reaction
PPTX
Homology modelling
PPTX
Denovo Drug Design
PPTX
Tumour targeting and Brain specific drug delivery
Structure based drug design
Computer aided drug design(CADD)
Drug Designing
Computer aided drug designing
Photo fries rearrangement & Barton reaction
Homology modelling
Denovo Drug Design
Tumour targeting and Brain specific drug delivery

What's hot (20)

PPTX
Molecular docking
PDF
Pharmacophore modeling
PPT
Rational drug design
PPT
Structure based drug designing
PPTX
Molecular docking
PPTX
PPTX
Molecular modelling
PPTX
Molecular docking
PPTX
molecular docking its types and de novo drug design and application and softw...
PPTX
docking
PPTX
SAR & QSAR
PPT
Computer aided drug design
 
PPTX
Virtual screening techniques
PPTX
Pharmacophore
PPT
Docking
PPTX
Quantitative Structure Activity Relationship
PPTX
CoMFA CoMFA Comparative Molecular Field Analysis)
PPTX
Quantitative Structure Activity Relationship (QSAR)
PPT
Pharmacophore identification
PPTX
Basics Of Molecular Docking
Molecular docking
Pharmacophore modeling
Rational drug design
Structure based drug designing
Molecular docking
Molecular modelling
Molecular docking
molecular docking its types and de novo drug design and application and softw...
docking
SAR & QSAR
Computer aided drug design
 
Virtual screening techniques
Pharmacophore
Docking
Quantitative Structure Activity Relationship
CoMFA CoMFA Comparative Molecular Field Analysis)
Quantitative Structure Activity Relationship (QSAR)
Pharmacophore identification
Basics Of Molecular Docking
Ad

Similar to Structure based and ligand based drug designing (20)

PPTX
Molecular Docking and its Applications.pptx
PPT
Cadd and molecular modeling for M.Pharm
PDF
43_EMIJ-06-00212.pdf
PPTX
Computational Drug Design
PPT
Significance of computational tools in drug discovery
PPTX
Protein 3 d structure prediction
PDF
E0362430
PPTX
molecular docking team12_1RV22EC-079,096,098,122.pptx
PPTX
threading and fold recognition bioinformatics
PPT
Drug design based on bioinformatic tools
PPTX
cadd-191129134050 (1).pptx
PPTX
Molecular docking.pptx
PDF
Determining stable ligand orientation
PDF
Virtual screening
PPTX
MOLECULAR DOCKING.pptx
PPTX
molecular docking screnning. pptx
PPT
QSPR For Pharmacokinetics
PPTX
MOLECULAR DOCKING IN DRUG DESIGN AND DEVELOPMENT BY PRANAVI linkedin.pptx
PPTX
Docking Techniques in Medicinal Chemistry by Rishabh Tiwari.pptx
Molecular Docking and its Applications.pptx
Cadd and molecular modeling for M.Pharm
43_EMIJ-06-00212.pdf
Computational Drug Design
Significance of computational tools in drug discovery
Protein 3 d structure prediction
E0362430
molecular docking team12_1RV22EC-079,096,098,122.pptx
threading and fold recognition bioinformatics
Drug design based on bioinformatic tools
cadd-191129134050 (1).pptx
Molecular docking.pptx
Determining stable ligand orientation
Virtual screening
MOLECULAR DOCKING.pptx
molecular docking screnning. pptx
QSPR For Pharmacokinetics
MOLECULAR DOCKING IN DRUG DESIGN AND DEVELOPMENT BY PRANAVI linkedin.pptx
Docking Techniques in Medicinal Chemistry by Rishabh Tiwari.pptx
Ad

More from Dr Vysakh Mohan M (10)

PPT
AI in beef cattle
PDF
Meat Inspection in Zoos
PPTX
Tannery Waste Management
PPTX
Effect of Age of Cattle on Carcass Composition
PPTX
Laboratory Animals - Taxonomic Classification
PPTX
LAMP - Loop-mediated isothermal amplificaton of DNA
PPTX
Doping in horses
PPTX
Awards and Campaigns Related to Alternative Animal Use
PPTX
STC411 Computer Simulation Techniques
PPTX
AI in beef cattle
Meat Inspection in Zoos
Tannery Waste Management
Effect of Age of Cattle on Carcass Composition
Laboratory Animals - Taxonomic Classification
LAMP - Loop-mediated isothermal amplificaton of DNA
Doping in horses
Awards and Campaigns Related to Alternative Animal Use
STC411 Computer Simulation Techniques

Recently uploaded (20)

PDF
Gynecologic Malignancies.Dawit.pdf............
PDF
Integrating Traditional Medicine with Modern Engineering Solutions (www.kiu....
PPTX
Methods of population control Community Medicine
PPTX
Hyperthyroidism, Thyrotoxicosis, Grave's Disease with MCQs.pptx
PDF
Nursing manual for conscious sedation.pdf
PPTX
Journal Article Review - Ankolysing Spondylitis - Dr Manasa.pptx
PPTX
PARASYMPATHETIC NERVOUS SYSTEM and its correlation with HEART .pptx
PPTX
Indications for Surgical Delivery...pptx
PDF
495958952-Techno-Obstetric-sminiOSCE.pdf
PPTX
SUMMARY OF EAR, NOSE AND THROAT DISORDERS INCLUDING DEFINITION, CAUSES, CLINI...
PPTX
Introduction to CDC (1).pptx for health science students
PPT
fiscal planning in nursing and administration
PPTX
presentation on causes and treatment of glomerular disorders
PPTX
IND is a submission to the food and drug administration (FDA), requesting per...
PDF
Diabetes mellitus - AMBOSS.pdf
PPTX
Pharynx and larynx -4.............pptx
PPTX
INDA & ANDA presentation explains about the
PPTX
Type 2 Diabetes Mellitus (T2DM) Part 3 v2.pptx
PPTX
etomidate and ketamine action mechanism.pptx
PPTX
Hypertensive disorders in pregnancy.pptx
Gynecologic Malignancies.Dawit.pdf............
Integrating Traditional Medicine with Modern Engineering Solutions (www.kiu....
Methods of population control Community Medicine
Hyperthyroidism, Thyrotoxicosis, Grave's Disease with MCQs.pptx
Nursing manual for conscious sedation.pdf
Journal Article Review - Ankolysing Spondylitis - Dr Manasa.pptx
PARASYMPATHETIC NERVOUS SYSTEM and its correlation with HEART .pptx
Indications for Surgical Delivery...pptx
495958952-Techno-Obstetric-sminiOSCE.pdf
SUMMARY OF EAR, NOSE AND THROAT DISORDERS INCLUDING DEFINITION, CAUSES, CLINI...
Introduction to CDC (1).pptx for health science students
fiscal planning in nursing and administration
presentation on causes and treatment of glomerular disorders
IND is a submission to the food and drug administration (FDA), requesting per...
Diabetes mellitus - AMBOSS.pdf
Pharynx and larynx -4.............pptx
INDA & ANDA presentation explains about the
Type 2 Diabetes Mellitus (T2DM) Part 3 v2.pptx
etomidate and ketamine action mechanism.pptx
Hypertensive disorders in pregnancy.pptx

Structure based and ligand based drug designing

  • 1. STRUCTURE BASED AND LIGAND BASED DRUG DESIGNING VYSAKH MOHAN M DRUG DESIGNING
  • 2. INTRODUCTION  CADD STRUCTURE BASED DRUG DESIGNING LIGAND BASED DRUG DESIGNING
  • 4. STRUCTURE BASED AND LIGAND BASED DRUG DESIGNING STRUCTURE BASED  Don’t know ligands  Know receptor structures LIGAND BASED  Don’t know receptors  Know ligands
  • 7. STRUCTURE BASED DRUG DESIGNING  Three dimensional structure of the biological target  Obtained through x-ray crystallography or NMT spectroscopy  If experimental structure is not available, create a homology model of the target, based on the experimental structure of a related protein  Various automated computational procedures may be used
  • 8. STRUCTURE BASED DRUG DESIGNING  Protein structure determination  Docking  Binding free energy  Flexibility of protein-ligand complex  De novo evolution
  • 9. PROTEIN STUCTURE DETERMINATION  HOMOLOGY MODELING  Fast method to obtain protein structures  To ensure the rationality of modelled structures, checks on stereochemistry, energy profile, residue environments, and structure similarity are needed
  • 10. PROTEIN STUCTURE DETERMINATION  FOLDING RECOGNITION  Threading  Calculates the probabilities of 3D structures could form by given protein sequences  Both environment of residues interactions and protein surface area are considered in the threading protocol  Structure with highest probability is recommended to construct the protein model
  • 11. PROTEIN STUCTURE DETERMINATION  Ab initio PROTEIN MODELING  Based on physical principles, residue interaction center and lattice representation of a protein to build the target  Used when other protocols fail to predict and unknown protein structure  Identity and accuracy given by this modelling is lower than others
  • 12. PROTEIN STUCTURE DETERMINATION  HOT SPOT PREDICTION  One big issue in SBDD is to determine ligand active site  Determined using X-ray crystallography  But not possible for proteins that cannot be crystallised  Several binding site determination methods have been invented
  • 13. DOCKING  A method which predicts the preferred orientation of one molecule to a second when bound to each other to form a stable complex
  • 15. DOCKING TOOLS  AUTODOCK  Software AutoDock, developed by Olsen’s Laboratory  A program for docking small flexible ligands into a rigid 3D structure
  • 17. DOCKING TOOLS  CDOCKER  This protocol is a docking algorithm and retain all the advantages of full ligand flexibility  Uses a sphere to define an active site, so the knowledge of the binding site is not required  CHARMM based docking algorithm
  • 18. DOCKING TOOLS  FLEXIBLE DOCKING  Retains receptor flexibility during docking of flexible ligands  ChiFlex algorithm  LibDock program  Indicates the binding site where ligand polar and non-polar groups may be bound to the favourable positions of protein
  • 19. DOCKING TOOLS  LIGAND FIT  A grid-based method for calculating receptor- ligand interaction energies, which is crucial in initial ligand shape match to the receptor binding site  Consists of  Definition of active site  Analysis of ligand conformations  Docking of ligands to a selected site  Scoring of predicted poses
  • 21. DOCKING TOOLS  TRANSMEMBRANE PROTEIN MODELING  There are many medicines that target transmembrane protein (HER2 and GABA receptor)  Due to difficulties of crystallisation accurately analysing transmembrane protein is difficult  Since there is influence of phospholipid bilayer a membrane force field option can be included
  • 22. A modeled GABA receptor with membrane force field.
  • 23. BINDING FREE ENERGY  All the docking protocols discussed above do not include functions for calculating binding free energy energy of binding = energy of complex – energy of ligand – energy of receptor
  • 24. FLEXIBILITY OF PROTEIN- LIGAND COMPLEX  Flexibility of complex must be studied  The difference in result of flexible docking and LigandFit is due to difference in flexibility of molecules, such that: Flexibility = score of LigandFit – score of flexible docking  The result of molecular simulation is related to flexibility, and a positive relationship can be obtained in flexibility vs. molecular dynamics.
  • 25. De novo EVOLUTION  After docking program, we can modify ligands by two methods  Based on active site features to identify functional groups that can establish strong interactions with the receptor. Then, functional groups can be linked  Using the original ligand scaffolds to develop derivatives that can complement the receptor
  • 27. LIGAND-BASED DRUG DESIGN  Relies on knowledge of other molecules that bind to the biological target of interest  These other molecules may be used to derive a pharmacophore model  Alternatively, a QSAR relationship, in which a correlation between calculated properties of molecules and their experimentally determined biological activity, may be derived  QSAR may be used to predict the activity of new analogues
  • 28. LIGAND-BASED DRUG DESIGN  Quantitative structure-activity relationship (QSAR)  CoMFA  CoMSIA
  • 29. QUANTITATIVE STRUCTURE- ACTIVITY RELATIONSHIP  Employs statistics and analytical tools to investigate the relationship between the structures of ligands and their corresponding effects.  Mathematical models are built based on structural parameters to describe  Earlier 2D-QSAR, but 3D-QSAR have been adopted  3D-QSAR methodologies: CoMFA, CoMSIA
  • 30. CoMFA  Comparative molecular field analysis  Biological activity of a molecule is dependent of the surrounding molecular fields (Steric and electrostatic fields)  Has several problems
  • 31. CoMSIA  Comparative molecular similarity index analysis  Includes more additional field properties  Steric  Electrostatic  Hydrophobic  Hydrogen bond donor  Hydrogen bond acceptor  Can offer a more accurate structural-activity relationship than CoMFA
  • 32. CONCLUSION  Molecular simulation has a vital role in drug design and CADD  Fast, efficient and inexpensive tool to  Discover new possible ligands against a macromolecular target  Test library design ideas  Identify most promising scaffolds and R groups prior to synthesis